Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer

Richard B. Alexander, Francine Brady, Mary Sue Leffell, Van Tsai, Esteban Celis

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objectives. To determine if proteins known to be expressed by both benign and malignant prostate epithelium can be recognized by T cells from patients with prostate cancer. We examined 7 HLA-A2 patients with prostate cancer for evidence of T cell reactivity with prostate-specific antigen (PSA). Methods. Four peptides derived from PSA were chemically synthesized and shown to bind to HLA-A2. As a control, we also examined the immunogenic influenza matrix peptide Flu58-66 that binds to HLA-A2. These peptides were used to stimulate peripheral blood lymphocytes by in vitro stimulation. Results. In 1 patient, specific recognition of peptide PSA141-150 was observed. The remaining 6 patients had no reactivity with any PSA-derived peptide. The T cell line with specific recognition of peptide PSA141- 150 failed to recognize an autologous B cell blast line expressing endogenous PSA following infection with a recombinant PSA vaccinia virus construct. Three of the 7 patients demonstrated specific reactivity with Flu58-66. Conclusions. We found specific recognition of one PSA-derived peptide in 1 patient of 7 with prostate cancer. The peptide-specific lymphocyte cell line did not recognize endogenous PSA, suggesting that the peptide may not be produced by prostate cancer cells producing PSA. Specific recognition of PSA peptides was not common in our patients with prostate cancer. Whether such activity can be induced by vaccination strategies or can be therapeutic in men with established prostate cancer remains to be demonstrated.

Original languageEnglish (US)
Pages (from-to)150-157
Number of pages8
JournalUrology
Volume51
Issue number1
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
T-Lymphocytes
Peptides
HLA-A2 Antigen
Cell Line
Lymphocytes
Vaccinia virus
Human Influenza
Prostate
Vaccination
B-Lymphocytes
Epithelium

ASJC Scopus subject areas

  • Urology

Cite this

Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. / Alexander, Richard B.; Brady, Francine; Leffell, Mary Sue; Tsai, Van; Celis, Esteban.

In: Urology, Vol. 51, No. 1, 01.01.1998, p. 150-157.

Research output: Contribution to journalArticle

Alexander, Richard B. ; Brady, Francine ; Leffell, Mary Sue ; Tsai, Van ; Celis, Esteban. / Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. In: Urology. 1998 ; Vol. 51, No. 1. pp. 150-157.
@article{0d4ba5a10b374a67809055015541968e,
title = "Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer",
abstract = "Objectives. To determine if proteins known to be expressed by both benign and malignant prostate epithelium can be recognized by T cells from patients with prostate cancer. We examined 7 HLA-A2 patients with prostate cancer for evidence of T cell reactivity with prostate-specific antigen (PSA). Methods. Four peptides derived from PSA were chemically synthesized and shown to bind to HLA-A2. As a control, we also examined the immunogenic influenza matrix peptide Flu58-66 that binds to HLA-A2. These peptides were used to stimulate peripheral blood lymphocytes by in vitro stimulation. Results. In 1 patient, specific recognition of peptide PSA141-150 was observed. The remaining 6 patients had no reactivity with any PSA-derived peptide. The T cell line with specific recognition of peptide PSA141- 150 failed to recognize an autologous B cell blast line expressing endogenous PSA following infection with a recombinant PSA vaccinia virus construct. Three of the 7 patients demonstrated specific reactivity with Flu58-66. Conclusions. We found specific recognition of one PSA-derived peptide in 1 patient of 7 with prostate cancer. The peptide-specific lymphocyte cell line did not recognize endogenous PSA, suggesting that the peptide may not be produced by prostate cancer cells producing PSA. Specific recognition of PSA peptides was not common in our patients with prostate cancer. Whether such activity can be induced by vaccination strategies or can be therapeutic in men with established prostate cancer remains to be demonstrated.",
author = "Alexander, {Richard B.} and Francine Brady and Leffell, {Mary Sue} and Van Tsai and Esteban Celis",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0090-4295(97)00480-9",
language = "English (US)",
volume = "51",
pages = "150--157",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer

AU - Alexander, Richard B.

AU - Brady, Francine

AU - Leffell, Mary Sue

AU - Tsai, Van

AU - Celis, Esteban

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Objectives. To determine if proteins known to be expressed by both benign and malignant prostate epithelium can be recognized by T cells from patients with prostate cancer. We examined 7 HLA-A2 patients with prostate cancer for evidence of T cell reactivity with prostate-specific antigen (PSA). Methods. Four peptides derived from PSA were chemically synthesized and shown to bind to HLA-A2. As a control, we also examined the immunogenic influenza matrix peptide Flu58-66 that binds to HLA-A2. These peptides were used to stimulate peripheral blood lymphocytes by in vitro stimulation. Results. In 1 patient, specific recognition of peptide PSA141-150 was observed. The remaining 6 patients had no reactivity with any PSA-derived peptide. The T cell line with specific recognition of peptide PSA141- 150 failed to recognize an autologous B cell blast line expressing endogenous PSA following infection with a recombinant PSA vaccinia virus construct. Three of the 7 patients demonstrated specific reactivity with Flu58-66. Conclusions. We found specific recognition of one PSA-derived peptide in 1 patient of 7 with prostate cancer. The peptide-specific lymphocyte cell line did not recognize endogenous PSA, suggesting that the peptide may not be produced by prostate cancer cells producing PSA. Specific recognition of PSA peptides was not common in our patients with prostate cancer. Whether such activity can be induced by vaccination strategies or can be therapeutic in men with established prostate cancer remains to be demonstrated.

AB - Objectives. To determine if proteins known to be expressed by both benign and malignant prostate epithelium can be recognized by T cells from patients with prostate cancer. We examined 7 HLA-A2 patients with prostate cancer for evidence of T cell reactivity with prostate-specific antigen (PSA). Methods. Four peptides derived from PSA were chemically synthesized and shown to bind to HLA-A2. As a control, we also examined the immunogenic influenza matrix peptide Flu58-66 that binds to HLA-A2. These peptides were used to stimulate peripheral blood lymphocytes by in vitro stimulation. Results. In 1 patient, specific recognition of peptide PSA141-150 was observed. The remaining 6 patients had no reactivity with any PSA-derived peptide. The T cell line with specific recognition of peptide PSA141- 150 failed to recognize an autologous B cell blast line expressing endogenous PSA following infection with a recombinant PSA vaccinia virus construct. Three of the 7 patients demonstrated specific reactivity with Flu58-66. Conclusions. We found specific recognition of one PSA-derived peptide in 1 patient of 7 with prostate cancer. The peptide-specific lymphocyte cell line did not recognize endogenous PSA, suggesting that the peptide may not be produced by prostate cancer cells producing PSA. Specific recognition of PSA peptides was not common in our patients with prostate cancer. Whether such activity can be induced by vaccination strategies or can be therapeutic in men with established prostate cancer remains to be demonstrated.

UR - http://www.scopus.com/inward/record.url?scp=0031891159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031891159&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(97)00480-9

DO - 10.1016/S0090-4295(97)00480-9

M3 - Article

C2 - 9457311

AN - SCOPUS:0031891159

VL - 51

SP - 150

EP - 157

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -